Pharmacoeconomics of amifostine in ovarian cancer

Elizabeth Calhoun, C. L. Bennett

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Physicians are frequently pressured to make therapeutic decisions within a cost-effective framework to demonstrate value to managed care. Because cancer is a chronic disease, health care costs are known to be expensive and physicians must use their resources as efficiently as possible. Historically, economic analyses in oncology have emphasized survival as their clinical end point. Today, both government groups and professional organizations are moving toward making quality of life the clinical end point in determining the economics of chemotherapy. This report evaluates the cost and efficacy of amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) use in the treatment of advanced ovarian cancer using two pharmacoeconomic analyses. A cost-utility analysis performed in the United States indicated that inclusion of amifostine therapy had both a favorable clinical and cost-utility profile compared with other medical therapies. A second cost-benefit analysis, conducted in Canada, suggested that use of amifostine in patients with advanced ovarian cancer would be cost saving. Amifostine is a novel agent that protects against both chemotherapy- and radiotherapy-induced toxicities, such as nephrotoxicity, neutropenia, thrombocytopenia, peripheral neuropathy, mucositis, and xerostomia. These toxicities are disturbing to both patients and physicians alike. The results of these studies support the use of amifostine as a valuable resource both economically and clinically.

Original languageEnglish (US)
Pages (from-to)102-107
Number of pages6
JournalSeminars in Oncology
Volume26
Issue number2 SUPPL. 7
StatePublished - 1999
Externally publishedYes

Fingerprint

Amifostine
Pharmaceutical Economics
Ovarian Neoplasms
Costs and Cost Analysis
Physicians
Cost-Benefit Analysis
Economics
Drug Therapy
Xerostomia
Mucositis
Managed Care Programs
Peripheral Nervous System Diseases
Therapeutics
Neutropenia
Thrombocytopenia
Health Care Costs
Canada
Chronic Disease
Radiotherapy
Quality of Life

ASJC Scopus subject areas

  • Oncology

Cite this

Calhoun, E., & Bennett, C. L. (1999). Pharmacoeconomics of amifostine in ovarian cancer. Seminars in Oncology, 26(2 SUPPL. 7), 102-107.

Pharmacoeconomics of amifostine in ovarian cancer. / Calhoun, Elizabeth; Bennett, C. L.

In: Seminars in Oncology, Vol. 26, No. 2 SUPPL. 7, 1999, p. 102-107.

Research output: Contribution to journalArticle

Calhoun, E & Bennett, CL 1999, 'Pharmacoeconomics of amifostine in ovarian cancer', Seminars in Oncology, vol. 26, no. 2 SUPPL. 7, pp. 102-107.
Calhoun, Elizabeth ; Bennett, C. L. / Pharmacoeconomics of amifostine in ovarian cancer. In: Seminars in Oncology. 1999 ; Vol. 26, No. 2 SUPPL. 7. pp. 102-107.
@article{85b87ce1fa9847309a668e7bde634a33,
title = "Pharmacoeconomics of amifostine in ovarian cancer",
abstract = "Physicians are frequently pressured to make therapeutic decisions within a cost-effective framework to demonstrate value to managed care. Because cancer is a chronic disease, health care costs are known to be expensive and physicians must use their resources as efficiently as possible. Historically, economic analyses in oncology have emphasized survival as their clinical end point. Today, both government groups and professional organizations are moving toward making quality of life the clinical end point in determining the economics of chemotherapy. This report evaluates the cost and efficacy of amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) use in the treatment of advanced ovarian cancer using two pharmacoeconomic analyses. A cost-utility analysis performed in the United States indicated that inclusion of amifostine therapy had both a favorable clinical and cost-utility profile compared with other medical therapies. A second cost-benefit analysis, conducted in Canada, suggested that use of amifostine in patients with advanced ovarian cancer would be cost saving. Amifostine is a novel agent that protects against both chemotherapy- and radiotherapy-induced toxicities, such as nephrotoxicity, neutropenia, thrombocytopenia, peripheral neuropathy, mucositis, and xerostomia. These toxicities are disturbing to both patients and physicians alike. The results of these studies support the use of amifostine as a valuable resource both economically and clinically.",
author = "Elizabeth Calhoun and Bennett, {C. L.}",
year = "1999",
language = "English (US)",
volume = "26",
pages = "102--107",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 7",

}

TY - JOUR

T1 - Pharmacoeconomics of amifostine in ovarian cancer

AU - Calhoun, Elizabeth

AU - Bennett, C. L.

PY - 1999

Y1 - 1999

N2 - Physicians are frequently pressured to make therapeutic decisions within a cost-effective framework to demonstrate value to managed care. Because cancer is a chronic disease, health care costs are known to be expensive and physicians must use their resources as efficiently as possible. Historically, economic analyses in oncology have emphasized survival as their clinical end point. Today, both government groups and professional organizations are moving toward making quality of life the clinical end point in determining the economics of chemotherapy. This report evaluates the cost and efficacy of amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) use in the treatment of advanced ovarian cancer using two pharmacoeconomic analyses. A cost-utility analysis performed in the United States indicated that inclusion of amifostine therapy had both a favorable clinical and cost-utility profile compared with other medical therapies. A second cost-benefit analysis, conducted in Canada, suggested that use of amifostine in patients with advanced ovarian cancer would be cost saving. Amifostine is a novel agent that protects against both chemotherapy- and radiotherapy-induced toxicities, such as nephrotoxicity, neutropenia, thrombocytopenia, peripheral neuropathy, mucositis, and xerostomia. These toxicities are disturbing to both patients and physicians alike. The results of these studies support the use of amifostine as a valuable resource both economically and clinically.

AB - Physicians are frequently pressured to make therapeutic decisions within a cost-effective framework to demonstrate value to managed care. Because cancer is a chronic disease, health care costs are known to be expensive and physicians must use their resources as efficiently as possible. Historically, economic analyses in oncology have emphasized survival as their clinical end point. Today, both government groups and professional organizations are moving toward making quality of life the clinical end point in determining the economics of chemotherapy. This report evaluates the cost and efficacy of amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) use in the treatment of advanced ovarian cancer using two pharmacoeconomic analyses. A cost-utility analysis performed in the United States indicated that inclusion of amifostine therapy had both a favorable clinical and cost-utility profile compared with other medical therapies. A second cost-benefit analysis, conducted in Canada, suggested that use of amifostine in patients with advanced ovarian cancer would be cost saving. Amifostine is a novel agent that protects against both chemotherapy- and radiotherapy-induced toxicities, such as nephrotoxicity, neutropenia, thrombocytopenia, peripheral neuropathy, mucositis, and xerostomia. These toxicities are disturbing to both patients and physicians alike. The results of these studies support the use of amifostine as a valuable resource both economically and clinically.

UR - http://www.scopus.com/inward/record.url?scp=0033033045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033033045&partnerID=8YFLogxK

M3 - Article

C2 - 10348268

AN - SCOPUS:0033033045

VL - 26

SP - 102

EP - 107

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 7

ER -